{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:26:05Z","timestamp":1787761565484,"version":"build-2784847793"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"\n Context and Aims:<\/jats:title>\n To evaluate the efficacy and safety of biosimilar romiplostim in Indian patients with immune thrombocytopenic purpura (ITP).<\/jats:p>\n <\/jats:sec>\n \n Settings and Design:<\/jats:title>\n Multicentre, retrospective observational study.<\/jats:p>\n <\/jats:sec>\n \n Methods and Material:<\/jats:title>\n \n Patients with chronic ITP who received biosimilar romiplostim from July 2019 to March 2020 across 3 major hospitals in Guwahati, India, were included. The study outcomes were the platelet response (platelet count > 50 \u00d7 10\n 9<\/jats:sup>\n \/L), time to first response, number of dose-limiting events, and the median effective dose.\n <\/jats:p>\n <\/jats:sec>\n \n Statistical Analysis Used:<\/jats:title>\n Descriptive.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Of 32 patients included in this analysis, majority (59.4%) were females. The mean (SD) age was 40.37 (15.79) years, and mean age at ITP diagnosis was 38.53 years. The median number of romiplostim doses were 27.5 (range: 10-42) over a period of 10 months; median romiplostim dose used was 4.2 \u03bcg\/kg (range: 2.8-5 \u03bcg\/kg). Platelet response was achieved as early as after one week in 9 (28.12%) patients, which continued to increase to 24 (75%) patients after the second, 30 (93.75%) patients after the third and all 32 (100%) patients after four weeks of romiplostim administration. The median platelet count was 161 \u00d7 10\n 9<\/jats:sup>\n \/L. Dose reduction was done in a total of 21 patients. Thrombocytosis (46.88%), elevated liver enzymes (15.63%) and myalgia (15.63%) were the most common adverse events.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Biosimilar romiplostim was effective in achieving and maintaining platelet response without any new safety concerns in Indian adult patients with chronic ITP. The median effective dose of romiplostim required in our patients was lower as compared with the standard prescribed dose.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijpm.ijpm_1034_21","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T01:16:19Z","timestamp":1675127779000},"page":"96-100","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of biosimilar romiplostim in Indian patients with chronic immune thrombocytopenia"],"prefix":"10.4103","volume":"66","author":[{"given":"Asif","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandana","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslin L.","family":"Bora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Phukan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20240829","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"R2-18-20240829","first-page":"37","article-title":"Romiplostim as a treatment for immune thrombocytopenia: A review","volume":"6","author":"Chalmers","year":"2015","journal-title":"J Blood Med"},{"key":"R3-18-20240829","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s12325-015-0251-z","article-title":"Current management of primary immune thrombocytopenia","volume":"32","author":"Provan","year":"2015","journal-title":"Adv Ther"},{"key":"R4-18-20240829","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"R5-18-20240829","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"},{"key":"R6-18-20240829","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","article-title":"The incidence of idiopathic thrombocytopenic purpura in adults increases with age","volume":"94","author":"Frederiksen","year":"1999","journal-title":"Blood"},{"key":"R7-18-20240829","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","article-title":"Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients","volume":"122","author":"Neylon","year":"2003","journal-title":"Br J Haematol"},{"key":"R8-18-20240829","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.11582","article-title":"Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: A critical appraisal from a systematic review of the literature","volume":"93","author":"Ruggeri","year":"2008","journal-title":"Haematologica"},{"key":"R9-18-20240829","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"Portielje","year":"2001","journal-title":"Blood"},{"key":"R10-18-20240829","first-page":"1690","article-title":"Romiplostim: A novel c-Mpl\/CD110 receptor ligand for the management of idiopathic thrombocytopenic purpura","volume":"3","author":"Patel","year":"2009","journal-title":"J Clin Diagn Res"},{"key":"R11-18-20240829","first-page":"305","article-title":"Long-term management of chronic immune thrombocytopenic purpura in adults","volume":"3","author":"Palau","year":"2010","journal-title":"Int J Gen Med"},{"key":"R12-18-20240829","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"R13-18-20240829","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R14-18-20240829","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"key":"R15-18-20240829","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"R16-18-20240829","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"key":"R17-18-20240829","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12185-011-0886-8","article-title":"Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: A double-blind, randomized phase III clinical trial","volume":"94","author":"Shirasugi","year":"2011","journal-title":"Int J Hematol"},{"key":"R19-18-20240829","first-page":"e9920","article-title":"Romiplostim and eltrombopag in immune thrombocytopenia as a second-line treatment","volume":"12","author":"Bidika","year":"2020","journal-title":"Cureus"},{"key":"R20-18-20240829","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"R21-18-20240829","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/2040620712453596","article-title":"The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia","volume":"3","author":"Cooper","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"R22-18-20240829","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3324\/haematol.2012.074633","article-title":"A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia","volume":"98","author":"Khellaf","year":"2013","journal-title":"Haematologica"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_1034_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:01:35Z","timestamp":1787760095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_1034_21"}},"subtitle":["A multicentric retrospective study"],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_1034_21","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}